The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
EYE on CHINA
Baxter China partners with government to increase access to renal therapy
Baxter China has partnered with the Chinese National Institute of Hospital Administration under an endorsement from the Ministry of Health to develop and deploy a sustainable care and delivery model for peritoneal dialysis (PD) patients with end-stage renal disease (ESRD), or irreversible kidney failure, living in rural areas of the country. Peritoneal dialysis is a home-based therapy in which patients infuse a solution through a surgically implanted catheter in their abdomen into their peritoneum, or abdominal cavity, where it draws waste products across the peritoneal membrane (which serves as a natural filter) into the solution.

The program, named “Flying Angel” for its intent to address the barriers to access for dialysis therapy in rural areas, piloted in six provinces beginning in early 2012. The majority of ESRD patients in rural China have limited access to care and therapy due to low awareness levels of the disease and limited hospital infrastructure and personnel. China’s Ministry of Health ranked ESRD among the country’s top eight critical diseases in 2012. Currently only a minority of the estimated one million patients in China with ESRD receive regular treatment.

The program will focus on establishing a logistics distribution model, standards of care, public education programs, training for healthcare professionals and improving affordability for patients.

Click here for the complete issue.